GlassScriptPhysician profile
Deng Zhang
NPI 1770894354
$17,855.91
in general payments reported to CMS, 2019-2025
52 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $198 · 2021: $4,810 · 2022: $2,146 · 2023: $4,599 · 2024: $3,656 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,244 · Consulting Fee: $2,820 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,584 · Education: $488 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,243.79 |
| Consulting Fee | $2,820.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,584.00 |
| Education | $487.52 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $2,366.19 | 2021-2023 | Xpovio |
| Eli Lilly and Company | $2,300.00 | 2021 | |
| Daiichi Sankyo INC. | $2,078.69 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Foundation Medicine, INC. | $1,811.44 | 2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Cti Biopharma Corp. | $1,460.89 | 2022-2023 | Vonjo |
| Astrazeneca Pharmaceuticals LP | $885.96 | 2022-2025 | Calquence, Enhertu, Lynparza |
| Beigene USA, INC. | $765.97 | 2020-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $725.59 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $413.94 | 2019-2025 | Opdivo, Opdualag |
| Abbvie INC. | $348.71 | 2021-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $325.19 | 2019-2023 | Imbruvica |
| Pfizer INC. | $324.88 | 2023-2025 | |
| Genzyme Corporation | $323.12 | 2019-2025 | |
| Incyte Corporation | $300.07 | 2020-2025 | Jakafi, Monjuvi |
| Gilead Sciences, INC. | $274.11 | 2023-2025 | Trodelvy |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $273.53 | 2023-2025 | Rybrevant, Darzalex, Erleada |
| Seagen INC. | $228.62 | 2019-2023 | Padcev |
| Astellas Pharma US INC | $207.32 | 2022-2025 | Xospata, Xtandi, Vyloy |
| Merck Sharp & Dohme LLC | $185.20 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $152.22 | 2022-2025 | Reblozyl |
| Puma Biotechnology, INC. | $144.80 | 2021-2025 | |
| Eisai INC. | $140.72 | 2020-2025 | |
| Sobi, INC | $125.03 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $124.21 | 2022-2025 | Monoferric |
| Tersera Therapeutics LLC | $119.64 | 2023-2025 | Zoladex |
| Amgen INC. | $106.91 | 2022-2023 | Kyprolis, Lumakras |
| Genmab U.S., INC. | $105.44 | 2023-2025 | Epkinly, Tivdak |
| Regeneron Healthcare Solutions, INC. | $103.78 | 2023-2025 | Libtayo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Acrotech Biopharma INC. | $98.09 | 2023-2024 | Beleodaq |
| Servier Pharmaceuticals LLC | $91.27 | 2024-2025 | |
| Genentech USA, INC. | $87.78 | 2023-2025 | Rozlytrek, Tecentriq, Alecensa |
| Kite Pharma, INC. | $83.42 | 2025 | Yescarta |
| Array Biopharma INC | $77.86 | 2022-2025 | Mektovi, Braftovi, Xalkori |
| Adaptive Biotechnologies Corporation | $66.46 | 2024-2025 | Clonoseq |
| Exelixis INC. | $60.94 | 2023-2025 | Cabometyx |
| Geron Corporation | $49.04 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.88 | 2025 | |
| Aveo Pharmaceuticals, INC. | $40.00 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $37.16 | 2022 | |
| Octapharma USA, INC. | $33.50 | 2023 | Panzyga |
| Caris Mpi, INC. | $32.67 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $32.47 | 2025 | Fruzaqla |
| Glaxosmithkline, LLC. | $32.29 | 2023-2025 | Ojjaara, Zejula |
| Rigel Pharmaceuticals, INC. | $25.54 | 2022-2023 | Rezlidhia, Tavalisse |
| Adc Therapeutics America, INC. | $24.46 | 2025 | |
| Coherus Oncology, INC. | $24.21 | 2024 | |
| Emd Serono, INC. | $21.80 | 2023 | Tepmetko |
| Sun Pharmaceutical Industries INC. | $19.71 | 2023 | Yonsa, Odomzo |
| Azurity Pharmaceuticals, INC. | $19.23 | 2024 | Vivimusta |
| Alexion Pharmaceuticals, INC. | $19.08 | 2023 | Ultomiris |
| Taiho Oncology, INC. | $15.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deng Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.